Table 5.
Health outcomes, direct costs, and ICER for secukinumab 150 mg vs comparators over a lifetime horizon (60 years)
| Administration | Treatment | Total state (€) | QALYs | Time spent in BASDAI 50 responder state (in years) | ICER costs (secukinumab vs comparator) |
|---|---|---|---|---|---|
| Subcutaneous | Secukinumab | 279,872 | 13.1 | 27.9 | |
| Certolizumab pegol | 309,257 | 12.6 | 26.7 | Secukinumab dominates | |
| Etanercept | 305,883 | 12.1 | 25.9 | Secukinumab dominates | |
| Etanercept biosimilar | 300,075 | 12.1 | 25.9 | Secukinumab dominates | |
| Adalimumab | 312,139 | 12.5 | 26.5 | Secukinumab dominates | |
| Adalimumab biosimilar | 297,282 | 12.5 | 26.5 | Secukinumab dominates | |
| Golimumab | 309,551 | 12.9 | 27.1 | Secukinumab dominates | |
| Intravenous | Infliximab | 316,291 | 12.6 | 26.2 | Secukinumab dominates |
Abbreviations: BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ICER, Incremental cost-effectiveness ratio; QALYs, quality-adjusted life years.